Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
But NASH Candidate Generates Interest
Executive Summary
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.
You may also be interested in...
J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn
Investment from Janssen helps to validate the platform developed by the San Diego-based company.
COVID-19 Vaccine Could Cost As Little As $10 A Dose, Says Janssen
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Moderna Not Immune To COVID-19 Effects On Trials
Company suspends enrolment to trials as coronavirus travel restrictions bite.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports